NasdaqGS:HALOBiotechs
Is Halozyme Therapeutics (HALO) Fully Valued After Its 107% Gain?
Halozyme Therapeutics has more than doubled investors' money over the past five years, yet its valuation checks and current market pricing suggest the stock is not an obvious bargain at today's levels.
A 107.1% total return over five years points to strong shareholder gains that raise the bar for what future performance needs to justify.
The recent collaboration with Incyte around ENHANZE based subcutaneous INCA033989 can support sentiment on long term revenue potential, while ongoing...